News | Congenital Heart | June 03, 2019

Hypertension Found in Children Exposed to Flower Pesticides

In Ecuador, roses for Mother’s Day sold around the world is major export crop, but pesticides used to grow and treat those flowers may be affecting health of children living nearby

Hypertension Found in Children Exposed to Flower Pesticides

June 3, 2019 — Researchers at University of California San Diego School of Medicine found higher blood pressure and pesticide exposures in children associated with a heightened pesticide spraying period around the Mother’s Day flower harvest. The study, published online in the journal Environmental Research,[1] involved boys and girls living near flower crops in Ecuador.

Mother’s Day is celebrated in May in most of the world and is a holiday with one of the highest sales of flowers. Ecuador is among the largest commercial flower growers in the world, with significant rose exports to North America, Europe and Asia. Commercial rose production relies on the use of insecticides, fungicides and other pest controls, but little is known about their human health effects.

“These findings are noteworthy in that this is the first study to describe that pesticide spray seasons not only can increase the exposure to pesticides of children living near agriculture, but can increase their blood pressures and overall risk for hypertension,” said first author Jose R. Suarez, M.D., Ph.D., assistant professor in the Department of Family Medicine and Public Health at UC San Diego School of Medicine.

Researchers assessed 313 boys and girls, ages 4 to 9, residing in floricultural communities in Ecuador. The children were examined up to 100 days after the Mother’s Day harvest. The analyses are part of a long-term study of environmental pollutants and child development in Ecuador, directed by Suarez.

“We observed that children examined sooner after the Mother’s Day harvest had higher pesticide exposures and higher systolic and diastolic blood pressures compared to children examined later. In addition, children who were examined within 81 days after the harvest were three times more likely to have hypertension than children examined between 91 and 100 days.”

Research regarding the effects of pesticides on the cardiovascular system is limited, but Suarez said there is some evidence that insecticides, such as organophosphates, can increase blood pressure. Organophosphates and several other classes of insecticides and fungicides are commonly used to treat flowers for pests before export.

In a previous study,[2] Suarez and colleagues had reported that children examined sooner after the harvest displayed lower performances in tasks of attention, self-control, visuospatial processing and sensorimotor than children examined later.

“These new findings build upon a growing number of studies describing that pesticide spray seasons may be affecting the development of children living near agricultural spray sites,” said Suarez. “They highlight the importance of reducing the exposures to pesticides of children and families living near agriculture.”

For more information: www.sciencedirect.com

 

References

1. Suarez-Lopez J.R., Amchich F., Murillo J., Denenberg J. Blood pressure after a heightened pesticide spray period among children living in agricultural communities in Ecuador. Environmental Research, published online May 21, 2019. https://doi.org/10.1016/j.envres.2019.05.030

2. Suarez-Lopez J.R., Checkoway H., Jacobs Jr. D.R., et al. Potential short-term neurobehavioral alterations in children associated with a peak pesticide spray season: The Mother’s Day flower harvest in Ecuador. NeuroToxicology, published online Feb. 7, 2017. https://doi.org/10.1016/j.neuro.2017.02.002

Related Content

FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
Overlay Init